Cadwalader Advises HealthCare Royalty Partners in $150 Million Royalty Agreement with Karyopharm Therapeutics

Oct 15, 2019

Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), Karyopharm’s oral SINE compound that is currently marketed in the United States for the treatment of patients with heavily pretreated multiple myeloma.

The Cadwalader team was led by partner Ira Schacter and included Joo Kim, Steve Lenkowsky and Solomon Brown.

CadwaladerNews

CadwaladerSpotlight

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.